Solasia Pharma KK (JP:4597)
:4597
Top Page
Solasia Pharma KK
(4597)
Select Model
Select Model
Rating:53Neutral
Price Target:
¥38.00
▲(40.74% Upside)
Action:ReiteratedDate:04/03/26
The score is held back primarily by weak financial performance (persistent losses and negative free cash flow), partially offset by a low-leverage balance sheet and improving revenue/loss trends. Technicals are supportive with price above key moving averages and positive momentum indicators, but valuation remains challenged due to loss-making earnings and no dividend support.
Positive Factors
Revenue Recovery & Growth
Revenue rebound in 2025 signals recovering product demand and improving commercial traction after several choppy years. Sustained top-line growth enhances operating leverage potential, reducing the scale of losses needed to approach breakeven and supporting longer-term investment plans.
Negative Factors
Persistent Operating & Net Losses
Large recurring operating and net losses—with a deeply negative 2025 net margin—show the cost base remains far above current revenue. Continued losses will erode equity over time, necessitate recurring financing or dilution, and make achieving sustainable profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery & Growth
Revenue rebound in 2025 signals recovering product demand and improving commercial traction after several choppy years. Sustained top-line growth enhances operating leverage potential, reducing the scale of losses needed to approach breakeven and supporting longer-term investment plans.
Read all positive factors
Solasia Pharma KK (4597) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.28B
Dividend YieldN/A
Average Volume (3M)41.98M
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth243.16%
EPS Growth-23.00%
CountryJP
Employees23
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.53
Shares Outstanding273,414,370
10 Day Avg. Volume52,616,870
30 Day Avg. Volume41,982,023
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.93
Price to Sales (P/S)16.06
P/FCF Ratio-8.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2
Revenue Forecast (FY)¥1.92B
Solasia Pharma KK Business Overview & Revenue Model
Company Description
Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis c...
How the Company Makes Money
null...
Solasia Pharma KK Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 429.00M | 316.00M | 617.00M | 1.09B | 559.00M |
| Gross Profit | 171.00M | -10.00M | -163.00M | 128.00M | -121.00M |
| EBITDA | -822.00M | -796.00M | -639.00M | -1.20B | -1.92B |
| Net Income | -876.00M | -1.94B | -1.11B | -2.55B | -2.48B |
Balance Sheet | |||||
| Total Assets | 2.15B | 1.36B | 2.55B | 3.56B | 3.76B |
| Cash, Cash Equivalents and Short-Term Investments | 1.39B | 886.00M | 728.00M | 803.00M | 714.00M |
| Total Debt | 159.00M | 25.00M | 60.00M | 37.00M | 84.00M |
| Total Liabilities | 392.00M | 203.00M | 673.00M | 899.00M | 1.17B |
| Stockholders Equity | 1.75B | 1.16B | 1.88B | 2.66B | 2.59B |
Cash Flow | |||||
| Free Cash Flow | -847.00M | -1.03B | -359.00M | -2.07B | -2.48B |
| Operating Cash Flow | -847.00M | -1.03B | -359.00M | -2.07B | -2.47B |
| Investing Cash Flow | -81.00M | 0.00 | 2.00M | -418.00M | -164.00M |
| Financing Cash Flow | 1.43B | 1.18B | 275.00M | 2.57B | 361.00M |
Solasia Pharma KK Technical Analysis
Positive
27.00
Price Trends
31.60
Positive
31.20
Positive
34.17
Positive
Market Momentum
0.76
Negative
57.23
Neutral
60.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4597, the sentiment is Positive. The current price of 27 is below the 20-day moving average (MA) of 32.60, below the 50-day MA of 31.60, and below the 200-day MA of 34.17, indicating a bullish trend. The MACD of 0.76 indicates Negative momentum. The RSI at 57.23 is Neutral, neither overbought nor oversold. The STOCH value of 60.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4597.
Solasia Pharma KK Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥14.87B | 16.22 | ― | ― | -5.41% | ― | |
64 Neutral | ¥6.23B | 11.64 | ― | 3.21% | 4.25% | ― | |
53 Neutral | ¥9.28B | -13.67 | -90.96% | ― | 243.16% | -23.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥6.10B | -12.20 | ― | ― | 56.17% | -11.63% | |
43 Neutral | ¥6.07B | -0.95 | ― | ― | -50.27% | -3.33% | |
41 Neutral | ¥5.08B | -2.01 | ― | ― | ― | 47.43% |
* Healthcare Sector Average
JP:4597
Solasia Pharma KK
34.00
2.00
6.25%
JP:4539
Nippon Chemiphar Co., Ltd.
1,725.00
317.98
22.60%
JP:4574
Taiko Pharmaceutical Co., Ltd.
297.00
36.00
13.79%
JP:4582
Symbio Pharmaceuticals Limited
102.00
-42.00
-29.17%
JP:4883
Modalis Therapeutics Corporation
55.00
-21.00
-27.63%
JP:4892
Cyfuse Biomedical K.K.
612.00
-377.00
-38.12%
Solasia Pharma KK Corporate Events
Solasia Pharma Advances Oncology Pipeline and Expands Global Reach for Key Cancer Drugs
Feb 13, 2026
Solasia Pharma has provided an update on its oncology and supportive care pipeline alongside its 2025 results, highlighting progress in marketed products and early-stage technology projects. The company is advancing nucleic acid medicine for perit...
Solasia Pharma Narrows Losses on Higher Sales but Withholds 2026 Outlook
Feb 13, 2026
Solasia Pharma reported a 35.4% year-on-year increase in consolidated sales to ¥429 million for the fiscal year ended December 31, 2025, but continued to post an operating loss of ¥861 million and a net loss attributable to owners of the...
Solasia Pharma Advances Oncology Pipeline and Expands Global Reach for Key Cancer Drugs
Feb 13, 2026
Solasia Pharma has updated investors on the status of its key pipeline and marketed products alongside its 2025 financial results, highlighting progress in commercialization and regional partnerships. In China, sales of Sancuso for chemotherapy-in...
Solasia Pharma Narrows Losses as Sales Rise but Withholds 2026 Forecast
Feb 13, 2026
Solasia Pharma reported a 35.4% year-on-year increase in consolidated sales to ¥429 million for the fiscal year ended December 31, 2025, while narrowing its operating loss to ¥861 million and net loss attributable to owners of the parent...
Solasia Grants MAAB Exclusive China Rights to Sancuso in Sales Framework Overhaul
Jan 23, 2026
Solasia Pharma has signed a license agreement granting MAAB Pharma exclusive marketing and manufacturing rights for its antiemetic patch Sancuso in mainland China, Hong Kong, Macau and Taiwan, as part of a restructuring of its sales framework in t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.